Shots:

• Synthekine to receive up front along with an additional one-time payment, if selects a second target & will be eligible for ~$525M in development, regulatory, and commercialization milestones along with royalties on net sales for each target
• Merck to get exclusive rights to develop, manufacture, and commercialize surrogate cytokine agonists for up to two cytokine targets. Synthekine is responsible for initial research efforts in collaboration with Merck
• The collaboration will utilize Synthekine’s surrogate cytokine agonist platform to discover, develop, and commercialize novel cytokine therapeutics for the treatment of autoimmune diseases

  Ref: Synthekine | Image: Merck